GlaxoSmithKline Pakistan Limited reported a strong financial performance for the year ended December 31, 2025
Filed as: Financial Results for the year Ended 2025-12-31
Summary
GlaxoSmithKline Pakistan Limited reported a strong financial performance for the year ended December 31, 2025, with revenue reaching Rs 65.90 billion and net profit increasing to Rs 10.03 billion.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Revenue | PKR 65.90 billion | PKR 61.19 billion | +7.7% |
| Net Profit | PKR 10.03 billion | PKR 6.54 billion | +53.4% |
| Gross Profit | PKR 24.38 billion | PKR 15.39 billion | +58.5% |
| Earnings Per Share | PKR 31.48 | PKR 20.52 | +53.4% |
| Operating Profit | PKR 16.85 billion | PKR 10.79 billion | +56.2% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Revenue increased by 7.70% to Rs 65.90 billion, indicating strong sales growth.
- Net profit surged by 53.41% to Rs 10.03 billion, reflecting improved profitability.
- Gross profit margin improved significantly, with gross profit rising to Rs 24.38 billion.
GlaxoSmithKline Pakistan Limited (GLAXO) on Nafa
Last price Rs 336.36 · Pharmaceuticals · You can own GLAXO shares from your phone.
More GLAXO announcements
- NoticeTransmission of Quarterly Report for the Period Ended September 30, 2026
- Financial resultGlaxoSmithKline Pakistan Limited reported a revenue of Rs 48.11 billion for the nine months ended September 30, 2026Filed as: Financial Results for the Quarter Ended September 30, 2026
- NoticeBoard Meeting Quarter 3-2026
- NoticeShariah Disclosure for the Half Year ended June 30, 2026
- NoticeCredit of Interim Cash Dividend
- NoticeAppointment of Chief Financial Officer
Source: GlaxoSmithKline Pakistan Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.